BioMarin Pharmaceutical $BMRN
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-35
RECRUITING3
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO60%
Delay Index: of 10 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open BioMarin Pharmaceutical on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PEGASUS NCT05270837 |
P3 | Active, not recruiting | Phenylketonuria (PKU) | 55 | 2025-01-14 (-11 mo) |
| GENEr8-JPN NCT06224907 |
P3 | Active, not recruiting | Hemophilia A | 6 | 2025-04-16 (+2 mo) |
| Vosoritide Injection NCT06382155 |
P2 | Recruiting | Idiopathic Short Stature | 100 | 2026-06 |
| BMN 351 NCT06280209 |
P1/2 | Active, not recruiting | Duchenne Muscular Dystrophy | 18 | 2027-04-14 (+16 mo) |
| vosoritide NCT04554940 |
P2 | Active, not recruiting | Achondroplasia | 20 | 2027-12 (+12 mo) |
| BMN 307 NCT04480567 |
P1/2 | Active, not recruiting | Phenylketonuria (PKU) | 100 | 2027-12 (+12 mo) |
| ACH NCT02724228 |
P2 | Active, not recruiting | Achondroplasia | 30 | 2027-12 (+62 mo) |
| Vosoritide NCT07126262 |
P2 | Recruiting | Hypochondroplasia | 60 | 2028-06-30 |
| HAErmony-1 NCT05121376 |
P1/2 | Active, not recruiting | Hereditary Angioedema; HAE | 44 | 2028-11 |
| ASPEN NCT07441876 |
P2/3 | Recruiting | Achondroplasia | 160 | 2029-06 |
| BMN 111 NCT03424018 |
P3 | Active, not recruiting | Achondroplasia | 119 | 2031-06 (+80 mo) |
| BMN 351 NCT07573631 |
P2 | Enrolling by invitation | Duchenne Muscular Dystrophy (DMD) | 18 | 2031-12 |
| Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. NCT03989947 |
P2 | Active, not recruiting | Achondroplasia | 73 | 2038-05 |
| CANOPY-HCH-EXT NCT07073014 |
P3 | Enrolling by invitation | Hypochondroplasia | 140 | 2044-10 (+46 mo) |